Becton Dickinson (BDX) will acquire C.R. Bard (BCR) in a $24 billion cash-and-stock deal, valuing C.R. Bard at $317 per share.
This is a 25 percent premium over Friday’s closing price. Bard shareholders will get $222.93 in cash and 0.5077 shares of Becton Dickinson for each of their shares.
The new combination will create a company with lead positions in syringes, infusion pumps, PICCs, ports, catheters, and other items.
C.R. Bard is a Dividend Hero and a Dividend Aristocrat.
C. R. Bard, Inc. is a developer, manufacturer and marketer of medical technologies in the fields of vascular, urology, oncology and surgical specialty products. The company sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.